Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 29, 2026Anticancer Research

Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJang-Hyuk YunSYSeongkyeong YooYNYOORIM NOH

Discussion

Loading...

Member takes

Overview

Randomized trial investigates AURKB inhibition reducing tumor growth in lung adenocarcinoma, suggesting a new therapeutic approach.

Key Points

  • This study investigates the role of AURKB in MYC-driven lung adenocarcinoma and its potential as a therapeutic target.
  • Analyzed AURKB expression and clinical significance using public cancer datasets.
  • Evaluated molecular interactions between AURKB and MYC signaling via Gene Set Enrichment Analysis.
  • Assessed the effects of AURKB inhibition on MYC target genes with siRNA or AZD2811 in in vitro studies and in a xenograft model.
  • High AURKB expression correlated with poor overall survival in LUAD patients.
  • Inhibition of AURKB decreased mRNA levels of MYC target genes CDC20, CCNA2, and CDC45.
  • Combined treatment with AZD2811 and MYCi361 significantly reduced tumor volume and weight compared to monotherapy.

Cite This Study

Yun et al. (2026) studied this question.

synapsesocial.com/papers/6a192f2dfab5b468c44189e4https://doi.org/10.21873/anticanres.18182
View Full Paper
Ask AI
Bookmark
Share